MedTrace Logo

Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management

NCT04343092 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-11-04

Study results available
· View outcomes & findings →

Summary

Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)

Conditions

  • COVID 19

Interventions

DRUG

Ivermectin (IVM)

Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly

Sponsors & Collaborators

  • University of Baghdad

    lead OTHER

Principal Investigators

  • Faiq I Gorial, Professor · University of Baghdad

  • Jawad I. Rasheed · Arab Board for Health Specialiazation in Iraq

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-18
Primary Completion
2020-05-31
Completion
2020-06-01

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343092 on ClinicalTrials.gov